33 completed, 2 terminated, 1 unknown, 1 withdrawn. 13 Phase 4, 11 Phase 2, 9 Phase 3, 5 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 12, Terminated 1 |
| Phase 2 | 11 | Completed 11 |
| Phase 3 | 9 | Completed 8, Withdrawn 1 |
| Phase 1 | 5 | Completed 5 |
| Not applicable | 1 | Terminated 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis WL8713, 6 mg, WL8713, 12 mg, WL8713, 18 mg - Hyperhidrosis | Phase 2 | Completed | Watson Pharmaceuticals | 195 | 2013-12-01 | 2015-08-06 |
| Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound - Polycystic Ovary Syndrome | Phase 2 / Phase 3 | Completed | Eastern Virginia Medical School | 52 | 2012-07-06 | 2018-02-26 |
| Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma Ulipristal Acetate, Iron - Leiomyomas | Phase 3 | Withdrawn | Watson Pharmaceuticals | 2012-04-01 | 2013-02-07 | |
| Examination of Serum Progesterone Levels in an IVF Population Following Two Types of Egg Aspiration Infertility, Female | Unknown | Red Rock Fertility Center | 450 | 2012-01-01 | 2012-01-20 | |
| Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems testosterone matrix transdermal system - Hypogonadism | Phase 2 | Completed | Watson Pharmaceuticals | 40 | 2011-04-01 | 2013-01-01 |
| Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Triptorelin pamoate, Leuprolide acetate - Prostate Cancer | Phase 4 | Completed | Watson Pharmaceuticals | 118 | 2010-07-01 | 2013-09-06 |
| Study of Silodosin to Facilitate Passage of Urinary Stones silodosin, placebo - Ureteral Calculi, Kidney Stones | Phase 2 | Completed | Watson Pharmaceuticals | 239 | 2010-06-01 | 2014-08-11 |
| Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception Norethindrone Acetate - Contraceptive Usage | Phase 3 | Completed | Watson Pharmaceuticals | 1659 | 2010-05-01 | 2013-09-19 |
| Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men Testerone Transdermal System - Hypogonadism | Phase 1 | Completed | Watson Pharmaceuticals | 40 | 2010-04-01 | 2012-10-05 |
| Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome 2% sodium chondroitin sulfate, Placebo - Interstitial Cystitis, Painful Bladder Syndrome | Phase 2 | Completed | Watson Pharmaceuticals | 98 | 2009-07-01 | 2013-05-03 |
| Effects of Oxybutynin Topical Gel on Gastric Emptying Oxybutynin Chloride Gel, Placebo Gel - Healthy | Phase 1 | Completed | Watson Pharmaceuticals | 23 | 2009-06-01 | 2012-10-08 |
| A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia silodosin - Nocturia, Prostatic Hyperplasia | Phase 2 | Completed | Watson Pharmaceuticals | 215 | 2009-01-01 | 2012-03-09 |
| Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Silodosin 8 mg, Placebo, Silodosin 4 mg - Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome | Phase 2 | Completed | Watson Pharmaceuticals | 153 | 2008-09-01 | 2012-02-24 |
| Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers oxybutynin chloride immediate-release, oxybutynin chloride topical gel, placebo - Healthy Volunteers | Phase 1 | Completed | Watson Pharmaceuticals | 153 | 2008-09-01 | 2011-09-23 |
| A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome. placebo, Uracyst - Interstitial Cystitis | Phase 2 | Completed | Watson Pharmaceuticals | 65 | 2007-09-01 | 2009-12-09 |
| Comparison Between Effects of Two Iron Preparations on Protein in the Urine iron sucrose injection, USP, sodium ferric gluconate complex in sucrose injection - Kidney Failure, Chronic, Anemia, Iron-Deficiency | Phase 1 | Completed | Watson Pharmaceuticals | 74 | 2007-09-01 | 2011-09-23 |
| A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo Oxybutynin topical gel, Placebo topical gel - Overactive Bladder | Phase 3 | Completed | Watson Pharmaceuticals | 789 | 2006-06-01 | 2010-05-10 |
| Effect of Two Iron Preparations on Protein in the Urine Sodium Ferric Gluconate and Iron sucrose - Kidney Failure, Chronic, Anemia, Iron-Deficiency | Phase 4 | Completed | Watson Pharmaceuticals | 12 | 2006-06-01 | 2012-08-14 |
| The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Silodosin - Benign Prostatic Hyperplasia | Phase 3 | Completed | Watson Pharmaceuticals | 661 | 2005-09-01 | 2010-04-27 |
| Low-Intensity Physical Therapy for Prevention of Pre and Postpartum Urinary Incontinence Pelvic Floor Muscle exercises - Urinary Incontinence | Not applicable | Terminated | University of Rochester | 23 | 2005-06-01 | 2011-11-03 |
Showing 20 of 37. Sign in to see all of them.
Anemia (6) · Anemia, Iron-Deficiency (6) · Kidney Failure, Chronic (5) · Iron Deficiencies (4) · Prostatic Hyperplasia (4) · Bronchiolitis Obliterans Syndrome (2) · Cystitis, Interstitial (2) · Hypogonadism (2) · Prostatic Neoplasms (2) · Renal Insufficiency (2) · Renal Insufficiency, Chronic (2) · Urinary Bladder, Overactive (2) · Urinary Incontinence (2) · Contraception Behavior (1) · Hyperhidrosis (1)
ferric gluconate (9) · silodosin (6) · Sucrose (5) · Triptorelin Pamoate (3) · oxybutynin (3) · Ferric Oxide, Saccharated (2) · Iron (2) · Iron-Dextran Complex (2) · Leuprolide (2) · Testosterone (2) · Administration, Cutaneous (1) · Buffers (1) · Chondroitin Sulfates (1) · Crinone (1) · Equipment and Supplies (1)
United States (35) · Canada (3) · Puerto Rico (3) · Mexico (2) · Poland (2) · Russia (2) · Brazil (1) · Bulgaria (1) · Croatia (1) · India (1) · Serbia (1)
Gary Hoel, RPh, PhD (4) · Kim Caramelli, MS (3) · Adel R. Rizkala, Pharm.D., MS (2) · Keshava Kumar, PhD, MHSA (2) · Lawrence Hill, PharmD, RPh (2) · Naomi V. Dahl, Pharm.D. (2) · Scott Olsen, MPH (2) · Adel R Rizkala, PharmD, MS (1) · Benoit Girard, M.D. (1) · Eva D Littman, M.D. (1) · Gunhilde Buchsbaum, MD (1) · Hermine I Brunner, M.D. M.Sc. (1) · Howard Zobrist, MS, PhD (1) · Jan L Shifren, MD (1)
PMID 21135869, PMID 23234617, PMID 16520948, PMID 17035697, PMID 17105798, PMID 17132474, PMID 17187655, PMID 17267740, PMID 17296819, PMID 17396118, PMID 17622274, PMID 17983434, PMID 18216316, PMID 19034302, PMID 19233423, PMID 19371887, PMID 19628264, PMID 19683731, PMID 19815265, PMID 20876669, PMID 21571345, PMID 22909146, PMID 24354113, PMID 25676588, PMID 37160401